<DOC>
	<DOC>NCT00018603</DOC>
	<brief_summary>This is a double-blind, placebo-controlled, randomized study lasting 8 weeks. Purpose of the study is two-fold: first, to use a pharmacological agent to treat symptoms of PTSD, and second, to explore neurobiological mechanisms of action of guanfacine.</brief_summary>
	<brief_title>Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)</brief_title>
	<detailed_description>Subject population is comprised of 100 persons with PTSD. 50 patients will receive guanfacine and 50 patients will receive a placebo. Guanfacine is prescribed at 1 mg/day and may be increased to 2 mg/day. Samples of plasma MHPG will be collected weekly. Clinical ratings of PTSD anxiety and depression, as well as vital signs, will be assessed weekly. Repeated measures analysis of variance will assess significance of main effect of drug, time, and drug by time.</detailed_description>
	<mesh_term>Stress Disorders, Traumatic</mesh_term>
	<mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>Males and females, age 1865 Diagnosis of PTSD from combat or civilian trauma No major medical problems such as diabetes, cardiovascular disease Taking no psychiatric medication, or taking only one SSRI antidepressant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>PTSD</keyword>
</DOC>